BioAdaptives Targets Multi-Billion Dollar Sleep Market with SleepEZ Natural Supplement
BioAdaptives’ SleepEZ™ Supplement Delivers Natural Sleep Support
Leading Sleep Experts Meet at the World Sleep Congress This Week to Discuss Latest Breakthroughs
Chronic Insomnia Affects an Estimated 30% of the World’s Population
LAS VEGAS, NV – 
(NewMediaWire) – October 26, 2023 – BioAdaptives, Inc. (OTC: BDPT), a leading formulator and distributor of innovative, all-natural dietary supplements, is targeting a multi-billion dollar industry with its popular, natural sleep supplement, SleepEZ™.
Chronic insomnia affects approximately 30% of the world’s population, including 50 to 70 million Americans who suffer from sleep disorders, which include insomnia, restless legs syndrome, narcolepsy and sleep apnea. Sleep plays a vital role in good health, and this week, the world’s foremost experts in sleep medicine have converged in Rio de Janeiro at the World Sleep Congress to discuss the latest developments across clinical and basic sleep and circadian research.
Edward Jacobs, M.D., BioAdaptives CEO, said, “BioAdaptives’ mission is to improve health and wellness for humans and animals through natural plant-based products, and we are proud to be at the forefront of delivering a natural sleep supplement to people living with sleep disorders.
“Difficulty sleeping is a common but neglected symptom that can have serious effects on health. Better quality sleep enables the body to boost immunity, reduce stress, and the risk of chronic diseases. Our SleepEZ™ supplement works with the circadian rhythm to promote restful and sustained sleep without the morning hangover drowsiness, an unwanted feature of many sleep aids.
“Additionally, our focus is always on delivering long term value for shareholders. Sleep EZ™ is one of BioAdaptives’ best selling products and part of our highly successful range of natural supplements aimed at optimizing pain relief, immune system defense and resistance to stress. We are targeting a slice of the global sleep aid market which was valued at $59 billion in 2020 and is projected to reach $111 billion by 2023.”
About SleepEZ™
SleepEZ™ is an all-natural supplement formula with origins in Traditional Chinese Medicine (TCM) featuring the optimal dose of high-quality ingredients. The most important component is XylariaⓇ (WulinshenPrimeTM), a proprietary extract from Xylaria nigripes. Published in vivo and human clinical trials have shown XylariaⓇ has mild to moderate effect in improving sleep quality, promoting relaxation, and elevating mood, but none of the side effects of prescription medications. XylariaⓇ reduces the amount of time taken to fall asleep (sleep latency) and also produces a calming effect due to Gamma-aminobutyric acid (GABA) and other synergetic constituents.
Additional ingredients include Lemon balm (Melissa officinalis), which encourages relaxation and reduces stress, Passionflower extract (Passiflora) which helps decrease anxiety and insomnia, and Chinese date (Zizyphus jujuba), which contains saponin, a natural sleep promoter.
About BioAdaptives, Inc.
BioAdaptives, Inc. develops and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, antiviral activity, and immune system defense; resistance to stress; endurance; recovery from injury, illness, and exercise; and anti-aging properties. The Company’s current dietary supplement formulations are carefully selected from the best sources around the world and utilize proprietary methods of enhancing the bioavailability of nutrients. BioAdaptives’ current product line includes PrimiLungs™, PluriPain®, SleepEZ™, MindnMemory™ and Cell Rejuven™ for humans. The Company’s products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance. BioAdaptives’ wholly owned subsidiary, LiveStock Impact, Inc markets Canine Regen All In One™, Equine All In One™ and Equine All In One Plus™ for dogs and horses. LiveStock Impact, Inc is also positioned to develop and market botanical drugs.
BioAdaptives’ common shares trade in the OTC market under the symbol BDPT. It has over 13,000 current shareholders. None of the statements about the Company’s products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Additional information can be found at www.shopbioadaptives.com or in our SEC filings at https://www.sec.gov/cgi-bin/browse-edgar?company=bioadaptives&owner=exclude&action=getcompany
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date after the date of this press release.
Contact
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
info@bioadaptives.com
View the original release on www.newmediawire.com
